These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

45 related articles for article (PubMed ID: 8587420)

  • 1. [3H]bosentan binding to human coronary artery: functional correlates.
    Dashwood MR; Timm M; Muddle JR; Shah D; Tippins JR; Kaski JC
    J Cardiovasc Pharmacol; 1995; 26 Suppl 3():S376-9. PubMed ID: 8587420
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protective effects of non-peptide endothelin receptor antagonist bosentan on myocardial ischaemic and reperfusion injury in the pig.
    Wang QD; Li XS; Lundberg JM; Pernow J
    Cardiovasc Res; 1995 Jun; 29(6):805-12. PubMed ID: 7656284
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Distribution of endothelin receptors in atherosclerotic human coronary arteries.
    Bacon CR; Cary NR; Davenport AP
    J Cardiovasc Pharmacol; 1995; 26 Suppl 3():S439-41. PubMed ID: 8587438
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regional variations in ETA/ETB binding sites in human coronary vasculature.
    Dashwood MR; Timm M; Kaski JC
    J Cardiovasc Pharmacol; 1995; 26 Suppl 3():S351-4. PubMed ID: 8587412
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Endothelin receptor subtypes and their functional relevance in human small coronary arteries.
    Pierre LN; Davenport AP
    Br J Pharmacol; 1998 Jun; 124(3):499-506. PubMed ID: 9647474
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacological characterization of bosentan, a new potent orally active nonpeptide endothelin receptor antagonist.
    Clozel M; Breu V; Gray GA; Kalina B; Löffler BM; Burri K; Cassal JM; Hirth G; Müller M; Neidhart W
    J Pharmacol Exp Ther; 1994 Jul; 270(1):228-35. PubMed ID: 8035319
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The nonpeptide endothelin receptor antagonist bosentan enhances myocardial recovery and endothelial function during reperfusion of the ischemic rat heart.
    Wang QD; Li XS; Pernow J
    J Cardiovasc Pharmacol; 1995; 26 Suppl 3():S445-7. PubMed ID: 8587441
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential effects of a novel non-peptide endothelin receptor antagonist (bosentan) in rat liver and vasculature.
    Phillips PA; Risvanis J; Aldred K; Burrell LM; Bartholomeusz B
    Clin Sci (Lond); 1995 Dec; 89(6):575-9. PubMed ID: 8549075
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of endothelin in the circulatory changes associated with small bowel strangulation obstruction in pigs: effects of the endothelin receptor antagonist bosentan.
    Fevang J; Ovrebø K; Myking O; Grong K; Svanes K
    J Surg Res; 2001 Apr; 96(2):224-32. PubMed ID: 11266277
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of the ETA receptor antagonist, FR 139317, on [125I]-ET-1 binding to the atherosclerotic human coronary artery.
    Dashwood MR; Allen SP; Luu TN; Muddle JR
    Br J Pharmacol; 1994 Jun; 112(2):386-9. PubMed ID: 7521255
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics and pharmacodynamics of the endothelin-receptor antagonist bosentan in healthy human subjects.
    Weber C; Schmitt R; Birnboeck H; Hopfgartner G; van Marle SP; Peeters PA; Jonkman JH; Jones CR
    Clin Pharmacol Ther; 1996 Aug; 60(2):124-37. PubMed ID: 8823230
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of endothelin receptors in the human pulmonary vasculature using bosentan, SB209670, and 97-139.
    Russell FD; Davenport AP
    J Cardiovasc Pharmacol; 1995; 26 Suppl 3():S346-7. PubMed ID: 8587410
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Autoradiographic localization of [125I]endothelin binding sites in human blood vessels and coronary tissue: functional correlates.
    Dashwood MR; Sykes RM; Muddle JR; Collins MJ; Prehar S; Theodoropoulos S; Yacoub MH
    J Cardiovasc Pharmacol; 1991; 17 Suppl 7():S458-62. PubMed ID: 1725412
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Separable binding sites for the natural agonist endothelin-1 and the non-peptide antagonist bosentan on human endothelin-A receptors.
    Breu V; Hashido K; Broger C; Miyamoto C; Furuichi Y; Hayes A; Kalina B; Löffler BM; Ramuz H; Clozel M
    Eur J Biochem; 1995 Jul; 231(1):266-70. PubMed ID: 7628480
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of peptide and nonpeptide antagonists in human kidney.
    Kuc RE; Karet FE; Davenport AP
    J Cardiovasc Pharmacol; 1995; 26 Suppl 3():S373-5. PubMed ID: 8587419
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardioprotective effect of an endothelin receptor antagonist during ischaemia/reperfusion in the severely atherosclerotic mouse heart.
    Gonon AT; Bulhak A; Bröijersén A; Pernow J
    Br J Pharmacol; 2005 Mar; 144(6):860-6. PubMed ID: 15685207
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Myricerone caffeoyl ester (50-235) is a non-peptide antagonist selective for human ETA receptors.
    Maguire JJ; Bacon CR; Fujimoto M; Davenport AP
    J Hypertens; 1994 Jun; 12(6):675-80. PubMed ID: 7963492
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Endothelin-1 in coronary artery disease].
    Myszka W; Kara-Perz H; Torliński L
    Pol Merkur Lekarski; 2001 Oct; 11(64):291-4. PubMed ID: 11770304
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Localization and characterization of endothelin-1 receptor binding in the blood vessels of human pulmonary tumors.
    Zhao YD; Springall DR; Hamid Q; Levene M; Polak JM
    J Cardiovasc Pharmacol; 1995; 26 Suppl 3():S341-5. PubMed ID: 8587409
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacological profile of ZD1611, a novel, orally active endothelin ETA receptor antagonist.
    Wilson C; Hunt SJ; Tang E; Wright N; Kelly E; Palmer S; Heys C; Mellor S; James R; Bialecki R
    J Pharmacol Exp Ther; 1999 Sep; 290(3):1085-91. PubMed ID: 10454481
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.